Scholarlink

<p>Mounting evidence indicates that NLRP3 inflammasome-mediated pyroptosis is critically involved in Parkinson’s disease (PD) pathogenesis. Sinomenine (SN) possesses neuroprotective properties and is known to modulate the NLRP3 inflammasome, but its potential to protect against PD via pyroptosis inhibition remains unexplored. This study demonstrates that SN confers significant neuroprotection in both cellular and animal PD models. Key findings show that SN alleviates motor deficits and nigral pathology in vivo, enhances neuronal viability, and suppresses pyroptosis in vitro. Mechanistically, SN potently inhibits NLRP3 inflammasome activation and subsequent cleavage of Caspase-1 and GSDMD, reducing levels of IL-1β and IL-18. The enhanced protection observed with the NLRP3 inhibitor MCC950 co-treatment validates the involvement of this pathway. Our results establish that SN mitigates PD-associated damage primarily by targeting the NLRP3/Caspase-1/GSDMD-mediated pyroptotic pathway.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroprotective effect of sinomenine on parkinson’s disease through NLRP3/Caspase-1/GSDMD pathway-mediated pyroptosis inhibition

  • 期刊论文

  • 发表日期：

    2026年1月20日

查看全文
  • Xi Bao,
  • JingCai Xu,
  • Jia Zhou,
  • Lin Huang,
  • HaiChang Li,
  • Yun Huang

摘要

Mounting evidence indicates that NLRP3 inflammasome-mediated pyroptosis is critically involved in Parkinson’s disease (PD) pathogenesis. Sinomenine (SN) possesses neuroprotective properties and is known to modulate the NLRP3 inflammasome, but its potential to protect against PD via pyroptosis inhibition remains unexplored. This study demonstrates that SN confers significant neuroprotection in both cellular and animal PD models. Key findings show that SN alleviates motor deficits and nigral pathology in vivo, enhances neuronal viability, and suppresses pyroptosis in vitro. Mechanistically, SN potently inhibits NLRP3 inflammasome activation and subsequent cleavage of Caspase-1 and GSDMD, reducing levels of IL-1β and IL-18. The enhanced protection observed with the NLRP3 inhibitor MCC950 co-treatment validates the involvement of this pathway. Our results establish that SN mitigates PD-associated damage primarily by targeting the NLRP3/Caspase-1/GSDMD-mediated pyroptotic pathway.

Graphical Abstract